DOI QR코드

DOI QR Code

고속 스크리닝 기법을 이용한 한약제제의 cytochrome P45O 저해능 탐색

Screening for inhibitory effect on nine CYP isoforms by 20 herbal medications

  • 김현미 (인제대학교 의과대학 약리학교실, 약물유전체연구센터) ;
  • 유광현 (인제대학교 의과대학 약리학교실, 약물유전체연구센터)
  • Kim, Hyun-Mi (Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine) ;
  • Liu, Kwang-Hyeon (Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine)
  • 발행 : 2007.03.30

초록

본 연구는 우황청심원을 비롯한 상용되는 20종의 한약제제를 대상으로 9종의 시토크롬 동종효소에 대한 대사능의 저해정도를 고속 스크리닝 기법을 이용하여 탐색함으로써, 한약제제와 약물의 병용으로 인한 약물 상호작용 가능성을 평가하고자 하였다. 인체 간 마이크로좀 시료에 9종의 주요 시토크롬 약물대사효소의 지표약물과NADPH-generating system및 한약제제(500 ${\mu}g/ml$)를 첨가한 후 $37^{\circ}C$에서 15분간 반응시켜 생성된 각각의 대사물을 LC/MS/MS를 이용하여 정량하여 시토크롬 동종효소 활성의 변화를 평가하였다. 그 결과 우황청심원 현탁액 및 황련해독탕 물 추출물이 각각 CYP2B6 및 CYP2D6 효소 활성을 선택적으로 강력하게 저해하였다. 이러한 결과는 약국에서 쉽게 구입할 수 있는 한약제제들 중 일부는 인체 간 시토크롬 활성 저해능을 가지고 있고, 이들 효소에 의해 대사되는 약물과의 병용 복용시 약물상호작용 발생 가능성이 있음을 의미한다. 향후 한약제제에서 저해능을 나타내는 주된 성분을 규명하여 이 성분의 저해능과 저해 기전을 살피는 노력이 필요할 것이다.

We evaluated the potential of 20 herbal medications (HMs), commonly used in Korea, to inhibit the catalytic activities of several cytochrome P450 (CYP) isoforms. The abilities of 500 ${\mu}g/ml$ of aqueous extracts of 20 HMs to inhibit phenacetin O-deethylation (CYP1A2), coumarin 6-hydroxylation (CYP2A6), bupropion hydroxylation (CYP2B6), rosiglitazone hydroxylation (CYP2C8), tolbutamide 4-methylhydroxylation (CYP2C9), S-mephenytoin 4'-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), chlorzoxazone 6-hydroxylation (CYP2E1), and midazolam 1'-hydroxylation (CYP3A) were tested using human liver microsomes. The HMs Woohwangcheongsimwon suspension and Hwanglyeonhaedok-Tang strongly inhibited CYP2B6 and CYP2D6 isoform activity, respectively. These results suggest that some of the HMs used in Korea have potential to inhibit CYP isoforms in vitro. Although the plasma concentrations of the active constituents of the HMs were not determined, some herbs could cause clinically significant interactions because the usual doses of those individual herbs are several grams of freeze-dried extracts.

키워드

참고문헌

  1. Chatterjee, P. and M. R. Franklin. 2003. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab. Dispos. 31, 1391-1397 https://doi.org/10.1124/dmd.31.11.1391
  2. De Smet, P. A. 2002. Herbal remedies. N. Engl. J. Med. 347, 2046-2056 https://doi.org/10.1056/NEJMra020398
  3. Guengelich, F. P. 1996. In vitro techniques for studying drug metabolism. J. Pharmacokinet. Biopharm. 24, 521-533 https://doi.org/10.1007/BF02353478
  4. Guengerich, F. P. 1997. Role of cytochrome P450 enzymes in drug-drug interactions. Adv. Pharmacol. 43, 7-35 https://doi.org/10.1016/S1054-3589(08)60200-8
  5. Guerra, M. C., E. Speroni, M. Broccoli, M. Cangini, P. Pasini, A. Minghett, N. Crespi-Perellino, M. Mirasoli, G. Cantelli-Forti and M. Paolini 2000. Comparison between chinese medical herb Pueraria lobata crude extract and its main isoflavone puerarin antioxidant properties and effects on rat liver CYP-catalysed drug metabolism. Life Sci. 67, 2997-3006 https://doi.org/10.1016/S0024-3205(00)00885-7
  6. Henderson, L., Q. Y. Yue, C. Bergquist, B. Gerden, and P. Arlett. 2002. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br. J. Clin. Pharmacol. 54, 349-356 https://doi.org/10.1046/j.1365-2125.2002.01683.x
  7. Hesse, L. M., K. Venkatakrishnan, M. H. Court, L. L. von Moltke, S. X. Duan, R. I. Shader and D. J. Greenblatt. 2000. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos. 28, 1176-1183
  8. Hwang, Y. S., C. Y. Shin, Y. Huh and J. H. Ryu. 2002. Hwangryun-Hae-Dok-tang (Huanglian-Jie-Du-Tang) extract and its constituents reduce ischemia-reperfusion brain injury and neutrophil infiltration in rats. Life Sci. 71, 2105-2017 https://doi.org/10.1016/S0024-3205(02)01920-3
  9. Ioannides, C. 2002. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 32, 451-478 https://doi.org/10.1080/00498250210124147
  10. Izzo, A. A. 2004. Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence. Int. J. Clin. Pharmacol. Ther. 42, 139-148 https://doi.org/10.5414/CPP42139
  11. Kim, M. J., H. Kim, I. J. Cha, J. S. Park, J. H. Shon, K. H. Liu and J. G. Shin. 2005. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 19, 2651-2658 https://doi.org/10.1002/rcm.2110
  12. Lee, M. S., H. J. Lim, M. S. Lee and H. S. Jang. 2005. Perceptions, knowledge and misuse of an oriental herbal drug: a survey of 608 Korean female nursing college students. Complement Ther. Clin. Pract. 11, 200-204 https://doi.org/10.1016/j.ctcp.2004.10.002
  13. Lu, T., Y. Liang, J. Song, L. Xie, G. J. Wang and X. D. Liu. 2006. Simultaneous determination of berberine and palmatine in rat plasma by HPLC-ESI-MS after oral administration of traditional Chinese medicinal preparation Huang-Lian-Jie-Du decoction and the pharmacokinetic application of the method. J. Pharm. Biomed. Anal. 40, 1218-1224 https://doi.org/10.1016/j.jpba.2005.09.023
  14. Markowitz, J. S., C. L. DeVane, D. W. Boulton, S. W. Carson, Z. Nahas and S. C. Risch. 2000. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci. 66, PL133-139 https://doi.org/10.1016/S0024-3205(99)00659-1
  15. Nakajima, M., K. Kobayashi, K. Oshima, N. Shimada, S. Tokudome, K. Chiba and T. Yokoi. 1999. Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. Xenobiotica 29, 885-898 https://doi.org/10.1080/004982599238137
  16. Thomas, K. J., J. P. Nicholl and P. Coleman. 2001. Use and expenditure on complementary medicine in England: a population based survey. Complement Ther. Med. 9, 2-11 https://doi.org/10.1054/ctim.2000.0407
  17. Ward, B. A., J. C. Gorski, D. R. Jones, S. D. Hall, D. A Flockhart and Z. Desta. 2003. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306, 287-300 https://doi.org/10.1124/jpet.103.049601
  18. Zhou, S., Y. Gao, W. Jiang, M. Huang, A. Xu and J. W. Paxton. 2003. Interactions of herbs with cytochrome P450. Drug Metab. Rev. 35, 35-98 https://doi.org/10.1081/DMR-120018248

피인용 문헌

  1. on Inflammation in RAW 264.7 Cells and the Activities of Drug-Metabolizing Enzymes in Human Hepatic Microsomes vol.21, pp.11, 2018, https://doi.org/10.1089/jmf.2017.4123